Key result
Intra-aortic balloon pumps and percutaneous ventricular assist devices (TandemHeart, Impella) provide therapeutic options for cardiogenic shock and high-risk percutaneous coronary intervention.
This review summarizes the characteristics and clinical evidence for percutaneous ventricular assist devices in managing cardiogenic shock and high-risk PCI.
These devices remain options for cardiogenic shock and high-risk PCI; leaves open optimal selection amid variable evidence.
SUMMARY Efficient therapy of cardiogenic shock and optimal protection in high-risk percutaneous coronary intervention are still orphaned to ideal management. Intra-aortic balloon pump and the newer percutaneous ventricular assist devices, such as TandemHeart and Impella Recover LP 2.5, have diversified the therapeutic arsenal with which one can tackle these clinical dilemmas. This article describes the characteristics of these three devices as well as the clinical evidence available for optimal and adapted use.
No takes yet. Share an insight, caveat, or question.
Arroyo et al. (2012) conducted a review in Cardiogenic shock and high-risk percutaneous coronary intervention. Percutaneous ventricular assist devices (TandemHeart, Impella Recover LP 2.5) and Intra-aortic balloon pump was evaluated. Intra-aortic balloon pumps and percutaneous ventricular assist devices (TandemHeart, Impella) provide therapeutic options for cardiogenic shock and high-risk percutaneous coronary intervention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: